These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 33846557)

  • 1. Defining values for controlled attenuation parameter and liver stiffness in youth without liver disease.
    Ramírez-Vélez R; García-Hermoso A; Correa-Rodríguez M; Izquierdo M
    Pediatr Res; 2022 Mar; 91(4):912-920. PubMed ID: 33846557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.
    Eddowes PJ; Sasso M; Allison M; Tsochatzis E; Anstee QM; Sheridan D; Guha IN; Cobbold JF; Deeks JJ; Paradis V; Bedossa P; Newsome PN
    Gastroenterology; 2019 May; 156(6):1717-1730. PubMed ID: 30689971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Feasibility study and reference values of FibroScan 502 with M probe in healthy preschool children aged 5 years.
    Zeng J; Zhang X; Sun C; Pan Q; Lu WY; Chen Q; Huang LS; Fan JG
    BMC Pediatr; 2019 Apr; 19(1):129. PubMed ID: 31018838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential impact of screening for fatty liver disease by transient elastography with liver stiffness and controlled attenuation parameter measurements: a pilot study.
    Peiseler M; Creutzfeldt A; Cassens I; Glaubke C; Kroll C; Lohse AW; Weiler-Normann C
    Z Gastroenterol; 2017 Aug; 55(8):754-760. PubMed ID: 28655068
    [No Abstract]   [Full Text] [Related]  

  • 5. Pediatric percentiles for transient elastography measurements - effects of age, sex, weight status and pubertal stage.
    Brunnert L; Puasa ID; Garten A; Penke M; Gaul S; Grafe N; Karlas T; Kiess W; Flemming G; Vogel M
    Front Endocrinol (Lausanne); 2022; 13():1030809. PubMed ID: 36237190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Accuracy of liver stiffness measurement and controlled attenuation parameter using FibroScan
    Oeda S; Takahashi H; Imajo K; Seko Y; Ogawa Y; Moriguchi M; Yoneda M; Anzai K; Aishima S; Kage M; Itoh Y; Nakajima A; Eguchi Y
    J Gastroenterol; 2020 Apr; 55(4):428-440. PubMed ID: 31654131
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Applicability and Results of Liver Stiffness Measurement and Controlled Attenuation Parameter Using XL Probe for Metabolic-Associated Fatty Liver Disease in Candidates to Bariatric Surgery. A Single-Center Observational Study.
    Wan T; Köhn N; Kröll D; Berzigotti A
    Obes Surg; 2021 Feb; 31(2):702-711. PubMed ID: 32959331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Usefulness of controlled attenuation parameter and liver stiffness measurement for detecting increased arterial stiffness in asymptomatic populations in China.
    Yu XY; Song XX; Tong YL; Wu LY; Song ZY
    Medicine (Baltimore); 2020 Nov; 99(48):e23360. PubMed ID: 33235107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utility of transient elastography (fibroscan) and impact of bariatric surgery on nonalcoholic fatty liver disease (NAFLD) in morbidly obese patients.
    Garg H; Aggarwal S; Shalimar ; Yadav R; Datta Gupta S; Agarwal L; Agarwal S
    Surg Obes Relat Dis; 2018 Jan; 14(1):81-91. PubMed ID: 29126863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Value of controlled attenuation parameter in fibrosis prediction in nonalcoholic steatohepatitis.
    Lee JI; Lee HW; Lee KS
    World J Gastroenterol; 2019 Sep; 25(33):4959-4969. PubMed ID: 31543686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved noninvasive prediction of liver fibrosis by liver stiffness measurement in patients with nonalcoholic fatty liver disease accounting for controlled attenuation parameter values.
    Petta S; Wong VW; Cammà C; Hiriart JB; Wong GL; Marra F; Vergniol J; Chan AW; Di Marco V; Merrouche W; Chan HL; Barbara M; Le-Bail B; Arena U; Craxì A; de Ledinghen V
    Hepatology; 2017 Apr; 65(4):1145-1155. PubMed ID: 27639088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic impact of liver fibrosis and steatosis by transient elastography for cardiovascular and mortality outcomes in individuals with nonalcoholic fatty liver disease and type 2 diabetes: the Rio de Janeiro Cohort Study.
    Cardoso CRL; Villela-Nogueira CA; Leite NC; Salles GF
    Cardiovasc Diabetol; 2021 Sep; 20(1):193. PubMed ID: 34560854
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Usefulness of Controlled Attenuation Parameter and Liver Stiffness Measurement for the Identification of Extended-criteria Donors and Risk-assessment in Liver Transplantation.
    Duarte-Rojo A; Heimbach JK; Borja-Cacho D; Barone GW; Shaheen MF; Lamps LW; Graham RP; Tan EK; Concepcion W; Kim WR
    Transplantation; 2022 Feb; 106(2):318-327. PubMed ID: 33675319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Moderate to severe hepatic steatosis leads to overestimation of liver stiffness measurement in chronic hepatitis B patients without significant fibrosis.
    Shen F; Mi YQ; Xu L; Liu YG; Wang XY; Pan Q; Zhang RN; Hu XQ; Xu LM; Fan JG
    Aliment Pharmacol Ther; 2019 Jul; 50(1):93-102. PubMed ID: 31094016
    [TBL] [Abstract][Full Text] [Related]  

  • 15. When the liver gets stiff, the tough get moving.
    Nguyen TH; Wardell R; Chitturi S; Teoh N; Farrell G
    J Gastroenterol Hepatol; 2020 Jun; 35(6):953-959. PubMed ID: 31867782
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum levels of soluble dipeptidyl peptidase-4 in type 2 diabetes are associated with severity of liver fibrosis evaluated by transient elastography (FibroScan) and the FAST (FibroScan-AST) score, a novel index of non-alcoholic steatohepatitis with significant fibrosis.
    Sagara M; Iijima T; Kase M; Kato K; Sakurai S; Tomaru T; Jojima T; Usui I; Aso Y
    J Diabetes Complications; 2021 May; 35(5):107885. PubMed ID: 33602617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prevalence of alcoholic and nonalcoholic fatty liver disease in adolescents and young adults in the United States: analysis of the NHANES database.
    Alkhouri N; Almomani A; Le P; Payne JY; Asaad I; Sakkal C; Vos M; Noureddin M; Kumar P
    BMC Gastroenterol; 2022 Jul; 22(1):366. PubMed ID: 35907827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors associated with significant liver steatosis and fibrosis as assessed by transient elastography in patients with one or more components of the metabolic syndrome.
    Mikolasevic I; Milic S; Orlic L; Stimac D; Franjic N; Targher G
    J Diabetes Complications; 2016; 30(7):1347-53. PubMed ID: 27324703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Controlled Attenuation Parameter (CAP): a noninvasive method for the detection of hepatic steatosis based on transient elastography.
    Myers RP; Pollett A; Kirsch R; Pomier-Layrargues G; Beaton M; Levstik M; Duarte-Rojo A; Wong D; Crotty P; Elkashab M
    Liver Int; 2012 Jul; 32(6):902-10. PubMed ID: 22435761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Feasibility of Fibroscan in Assessment of Hepatic Steatosis and Fibrosis in Obese Patients: Report From a General Internal Medicine Clinic.
    Avcu A; Kaya E; Yilmaz Y
    Turk J Gastroenterol; 2021 May; 32(5):466-472. PubMed ID: 34231477
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.